Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180035/S031

MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

CooperVision, Inc. · Decision date Oct 28, 2025

FDA DECISIONP180035/S031

What did the FDA approve?

FDA records P180035/S031 as a supplement to PMA P180035, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 28, 2025.

FDA approval order statement

Approval of protocol changes to enroll approximately 1000 subjects in PAS002 to achieve at least 4000 patient years total (approximately 2000 per study) with an average follow up of 2-3 years per subject. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P180035.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Ophthalmic
Decision date
Oct 28, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P180035/S031
Regulatory pathway
PMA supplement
Product code
QIT
Decision code
APPR
Decision date
Oct 28, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Daily wear soft contact lens to reduce the progression of myopia.

Product code
QIT
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180035/S030 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

  2. P180035/S031 received

    Application receipt date recorded by FDA.

  3. P180035/S031 · FDA decision

    Normal 180 Day Track No User Fee

  4. P180035/S032 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

  5. P180035/S033 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

  6. P180035/S034 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

Timeline entries are records held by MedtechLedger for P180035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180035

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

CooperVision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5870 Stoneridge Dr., Suite 1, Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records